Drugs / SPC 1001 Mid2
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT06826872 Comparator | Jun 2024 → Oct 2025 overdue | essential hypertension | Shin Poong Pharmaceutical Co. Ltd. | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SPC 1001 Mid2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06826872 ↗ |